Correspondingly, the expression level of SETMAR was significantly associated with various clinical characteristics of thyroid cancer, including clinical stage (Figure S1C, Supporting Information), T stage (Figure S1D, Supporting Information), lymph node metastasis (Figure S1E, Supporting Information), BRAFV600E mutation (Figure S1F, Supporting Information), disease‐free survival (Figure 1D), and progression‐free survival (Figure 1E). This evidence concerns the gene SETMAR and thyroid gland carcinoma.